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Vicenin-2  (apigenin-6,8-di-C--d-glucopyranoside)  is present  in hydroalcoholic  extracts  of the Brazilian
species  Lychnophora  ericoides  Mart.,  Asteraceae,  leaves,  and  the  biological  effects of  this  compound  have
been  demonstrated  including  anti-inﬂammatory,  antioxidant  and  anti-tumor  effects  in rat  models.  Given
the potential  of  this  compound  as  a pharmacological  agent,  the  aims  of  this  investigation  were  to  eval-
uate  the extent  of  intestinal  absorption  of  vicenin-2,  and  to determine  the intestinal  permeation  proﬁle
using  an  in  situ  single-pass  intestinal  perfusion  technique.  A  validated  HPLC–UV  method  was  applied  to
measure  the amount  of  unabsorbed  vicenin-2  in the  gut after  an oral  administration  of 180  mg  kg−1 in
ﬁve  rats.  A nonlinear  mixed  effects  model  was  used  to determine  the  absorption  pharmacokinetic  param-
eters  assuming  a  ﬁrst  order  absorption  and  active  secretion  processes  for this  compound,  wherein  the
active secretion  was  characterized  by a zero-order  process.  The  population  pharmacokinetic  parameters
obtained  were  0.274  min−1 for the  ﬁrst-order  absorption  rate constant,  16.3%  min−1 for the  zero-order
rate  constant;  the  ﬁnal  percentage  of  the original  dose  that  was  absorbed  in  vivo  was 40.2  ± 2.5%.  These
parameters  indicated  that  vicenin-2  was  rapidly  absorbed  in  the small  intestine.  In contrast  to  literature
information  indicating  no absorption  of vicenin-2  in  Caco-2  cells,  our  results  suggested  that  vicenin-2
can  be absorbed  in  the  small  intestine  of rats.  The  ﬁnding  supports  further  investigation  of  vicenin-2  as
a viable  oral  phytopharmaceutical  agent  for digestive  diseases.
©  2015  Sociedade  Brasileira  de  Farmacognosia.  Published  by  Elsevier  Editora  Ltda.  All  rights  reserved.ntroduction
There is an enormous growth of worldwide interest in herbal
edicines in both the developed and developing countries over
he last decades. The increasing market for botanical products has
ttracted much interest of some pharmaceutical companies, which
as in turn motivated pre-clinical pharmacological studies as well
s controlled and randomized clinical trials to prove the safety and
fﬁcacy of herbal products (Calixto, 2000). In addition to showing
harmacological activities, the pharmacokinetic properties of these
∗ Corresponding author at: Departamento de Farmácia, Universidade Estadual de
aringá, Maringá, PR, Brazil.
E-mail: adiniz@uem.br (A. Diniz).
http://dx.doi.org/10.1016/j.bjp.2015.04.001
102-695X/© 2015 Sociedade Brasileira de Farmacognosia. Published by Elsevier Editoraagents are key factors in determining whether a compound could
be a viable medicinal product (Sy and Derendorf, 2014; Sy et al.,
2014).
With growing interests in polyphenolic compounds as pharma-
cological agents, ﬂavonoid, belonging to this group, is the most
studied class of compounds; their pharmacological activities and
pharmacokinetic behaviors have been well characterized. Polyphe-
nolic compounds often have poor bioavailability, given that they are
substrates of both inﬂux and efﬂux transporters and are also sub-
jected to pre-systemic metabolism (Barnes, 2004; Gee et al., 2000).
Physiological pH, formation of conjugated metabolites including
glucuronide metabolites during its passage through the enterocytes
and even biotransformation by intestinal micro biota are known
to affect the disposition of vicenin-2 presystemically (Gobbo-Neto
et al., 2005).
 Ltda. All rights reserved.
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Most of the studies of ﬂavonoid absorption were performed
n the aglycone or O-glycosyl forms which have unstable glyco-
idic bonds that are easily hydrolyzed. In contrast, vicenin-2 (1),
hose chemical structure is shown below, is a C-glycosyl ﬂavonoid
hat tends to be more stable against hydrolysis than the O-glycosyl
avonoids.
HO
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his compound is found in the hydroalcoholic extracts of the leaves
f the Brazilian species Lychnophora ericoides Mart., Asteraceae, and
ome of its biological activities have already been characterized.
n recent study, investigators have demonstrated that L. ericoides
xtracts which are rich in vicenin-2 were effective as prophylac-
ic agent against the disease progression of colon cancer in the rat
odel (Fernandes et al., 2011). Other pharmacological action of
his compound included anti-inﬂammatory and antioxidant prop-
rties (Gobbo-Neto et al., 2005). These promising pharmacological
ffects prompted us to investigate and characterize the intestinal
bsorption of vicenin-2.
The in vitro and in situ absorption models, such as Caco-2 cell
onolayers, everted gut sacs and perfused animal intestine, are
ommonly used to investigate transport mechanisms, to classify
ermeability, and to predict in vivo absorption of drugs in humans
Lennernas et al., 1997). The in situ single-pass intestinal perfusion
echnique has an advantage such that it is carried out in live exper-
mental animals with intact blood supply and functional nervous
ystem. This methodology is found to be simple and highly accurate
or predicting intestinal absorption in humans (Fagerholm et al.,
996). The aims of this investigation are to evaluate the intestinal
bsorption of vicenin-2, to obtain the intestinal permeation proﬁle
or this glycosyl-ﬂavonoid, and to develop a mathematical model
escribing its absorption.
aterials and methods
hemicals
All solvents for chromatographic analysis were HPLC grade. All
ther reagents were P.A. grade. The vicenin-2 (1) was isolated from
ychnophora ericoides Mart., Asteraceae, according to the method-
logy previously described (Gobbo-Neto et al., 2005).
ingle-pass intestinal perfusion studies
All animal experiments were conducted using protocols
pproved by the Animal Experiment and Ethics Committee of Lon-
rina State University (protocol 107/09). Male albino Wistar rats,
eighing from 190 to 250 g were used for the perfusion studies.
rior to each experiment, the rats were fasted overnight, 12–18 hrmacognosia 25 (2015) 212–218 213
prior to experimentation. Water was freely available for these ani-
mals during the fasting period.
The in situ single-pass perfusion follows the procedure in
published reports (Fagerholm et al., 1996). Brieﬂy, the animals
were anesthetized with an intra-peritoneal injection of 40 mg  kg−1
of thiopental solution and were placed on a heated surface
maintained at 37 ◦C. For the perfusion, 10 ml isosmotic solution
(282–297 mOs  ml−1) was  prepared containing 5% of Tween 80 (v/v),
buffered at pH 6.4 with a vicenin-2 dose of 180 mg  kg−1(n = 5).
The remaining amount of drug in the intestinal lumen was
collected in the volume of 200 l per sample and measured
every 5 min, for a total time of 30 min, by a validated high-
performance liquid chromatography and ultraviolet detection
(HPLC–UV) method. The samples collected were ﬁrst centrifuged
at 140 × g for 15 min  and then frozen at −40 ◦C. No drug degra-
dation was  detected after freeze-thaw cycle. Water reabsorption
was evaluated for each animal. This process follows apparent zero-
order kinetics (Martin-Villodre et al., 1986; Ruiz-Balaguer et al.,
2002) and the remaining vicenin-2 concentrations were properly
corrected.
Analytical procedures
Intestinal perfused samples were assayed for vicenin-2 concen-
tration using HPLC–UV. Intestinal perfused samples were diluted
in 100 l of methanol: water (1:1, v/v) solution, ﬁltered across a
0.45 M membrane (Millipore®) and analyzed by chromatographic
system. The chromatographic system consists of a Shimadzu®HPLC
system which included LC 10 AD pump, UV detector, Class-VP sys-
tem, Rheodyne® 7125 manual injector with a 20 l loop. A Waters®
C18 analytical column Nova-Pak (3.9 × 150 mm)  and guard column
C-18 (5 mm,  Hamilton) was  used. The mobile phase was  a mixture
(20:80, v/v) of methanol and ultra-puriﬁed water, both containing
2% acetic acid at pH 2.3; the ﬂow rate was 0.8 ml min−1. The wave-
length used was 330 nm.  Calibration curves covering 7.0 – 40.0 mM
L–1 vicenin-2 concentrations in the luminal samples were prepared.
Pharmacokinetic analysis
The vicenin-2 concentrations in each sample represented the
remaining concentration in the intestinal lumen. It was assumed
that no degradation occurred during the experiment since no other
chromatographic peak was  observed at 254 nm and 330 nm,  which
were the wavelengths that produce the maximum excitation and
emission for ﬂavonoid and phenol rings.
The ﬁnal percentage absorbed (%Abs) was  determined using Eq.
(1):
%Abs  = Ct30
Ct0
× 100% (1)
where Ct30 is the vicenin-2 concentration at the last sample at
30 min  and Ct0 is the initial vicenin-2 concentration.
Flavonoids are substrates for the efﬂux protein expressed
in enterocyte membranes. Among the transporters, the P-
glycoprotein was the most studied (Li and Paxton, 2013; Tian et al.,
2009). Given that the ﬂavonoids are subject to active secretion
by the enterocytes, both the Michaelis–Menten equation and the
zero-order process to describe drug secretion into the lumen were
evaluated, similar to the models previously described (Munoz et al.,
2005).Model 1 is a ﬁrst-order absorption and zero-order secretion pro-
cess:
dA
dt
= −ka · A + k0 (2)
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Model 2 consists of a ﬁrst-order absorption and
ichaelis–Menten function representing active secretion:
dA
dt
= −ka · A + VmsAE
Kms + AE
(3)
Model 3 encompasses Michaelis–Menten absorption and active
ecretion processes:
dA
dt
= − VmA
Km + A +
VmsAE
Kms + AE
(4)
Model 4 incorporates a cosine function to the active secretion
rocess in Model 2:
dA
dt
= −ka · A + VmsAEKms + AE
· (cos2 t + 1) (5)
Model 5 also incorporates a cosine function to the zero-order
ecretion process in Model 1:
dA
dt
= −ka · A + k0 · (cos2 t + 1) (6)
here dA/dt is the absorption rate, A is the remaining vicenin-2
oncentrations in the gut, ka represents the ﬁrst order absorption
ate constant, Vms refers to the maximum secretion rate, Kms is
he concentration at which the secretion is half maximal, Vm is the
aximum absorption, Km is the concentration which results in half
aximum absorption, k0 is the zero-order secretion process, and
E is supposedly the vicenin-2 concentration in the enterocyte that
s achieved in ﬁrst 5 min. Given that A and AE are proportional, A,
epresenting the amount remaining in the gut, was used for AE.
The remaining concentration of vicenin-2 reported as a percent-
ge of the initial dose in each sample was used in the model ﬁt.
he models listed in Eqs. (1)–(5) were ﬁtted to the data from all
nimals, using Nonmem® version VII.2 (Buqui et al., 2015; Munoz
t al., 2005; Sy et al., 2013). The ﬁrst order conditional estima-
ion with interaction, using subroutine ADVAN9 and tolerance of
 was used. Between-animal variability in the model parameter
as assumed to be log-normally distributed. The Bayesian estimate
f individual model-predicted vicenin-2 remaining concentration
as evaluated with and without weighting factors by using addi-ive or proportional error models or the combination of both. Given
he exploratory nature of this study, model selection was  based
n maximum likelihood statistics, goodness-of-ﬁt plots (consist-
ng of population and individual predictions versus observations
able 1
opulation pharmacokinetic models and model parameter estimates for vicenin-2 absorp
Absorption First-order First-order Michaelis-Menten 
Secretion Zero-order Michaelis–Menten Michaelis–Menten 
Model  No. 1 2 3 
Parameter
ka (min−1) 0.274 (11%) 0.28 (9.2%) 
Vm  (% min−1) 91.7 (105%)
Km (%) 47,000 (130%)
k0 (% min−1) 16.3 (9.4%) 
Vms (% min−1) 17.2 (7.3%) 6.99 (84%) 
Kms (%) 18.2 (1.8%) 1.15 (295%) 
  (min−1)
Interindividual variability
%CV of ka 8.4 (75%) 8.2 (77%) 
%CV  of Vm 16.6 (90%)
%CV of  
Residual variability
Residual error 0.00154 (25%) 0.00154 (25%) 0.00148 (26%) 
MOFV  118.43 118.4 117.143 
alues reported as mean (relative standard error, %).
a No standard error of estimates reported due to matrix singularity. MOFV, minimum ormacognosia 25 (2015) 212–218
and conditional weighted residuals versus time and individual pre-
dictions) and visual predictive checks (VPC, with 1000 simulated
proﬁles). For hierarchical models, the difference in objective func-
tion value was -squared distributed. A p-value of 0.01 was used
as the criteria for selecting a more complex model over a reduced
one, corresponding to the difference in objective function value of
6.63. The evaluation of precision in the estimated parameter value
was based on the relative standard error.
The robustness of the ﬁnal model and parameter imprecision
was evaluated using a non-parametric bootstrap procedure. The
algorithm involves repeated random sampling of animals in the
study, with replacement of the original data set in each subsequent
sampling to produce another dataset of the same size as the original,
but with a different list of animals. The re-sampling was repeated
500 times. The ﬁnal population pharmacokinetic model was  ﬁtted
to each of the bootstrap datasets and a set of model parameters
were determined for each run. The median and 95% conﬁdence
intervals were computed and compared to the values from the orig-
inal Nonmem® analysis. Perl Speaks Nonmem® 3.5.5 running active
Perl® 5.10.1 (Active State Software Inc., Vancouver, BC, Canada)
were used to manage post-Nonmem analysis and Xpose® 4 running
on R® 2.14.0 for graphical evaluation.
Results
A chromatographic method using HPLC–UV was  developed and
validated for the quantiﬁcation of vicenin-2 that remained in the
gut of rats over a 30 min  period. The standard curve for calibration
showed excellent linear plots relating the peak area to solute con-
centration (r2 > 0.9990); the intercept of the linear regression did
not signiﬁcantly differ from zero. Accuracy was evaluated by cal-
culating the relative error, which was  less than 15%. Precision was
evaluated by calculating the coefﬁcient of variation, which was less
than 5%. These results were considered satisfactory.
The extent of vicenin-2 absorption computed from Eq. (1) was
40.2 ± 2.5%. The absorption proﬁles of vicenin-2 in six rats were
evaluated using ﬁve models. The parameter estimates for the ﬁve
models are listed in Table 1. As some studies have indicated that
ﬂavonoids are substrates of efﬂux transporters of the ATP binding
cassette family (ABCB1, p-glycoprotein) (Barnes, 2004; Fagerholm
et al., 1996; Gee et al., 2000), a Michaelis–Menten kinetic was incor-
porated to describe the active secretion process in Models 2 through
tion in rats.
Model description
First-order First-order
Michaelis–Menten with cosine function Zero-order with cosine function
4a 5a
0.502 0.291
8.78
9.55
12.1
1.21 1.88
60.5 0.0892
14.0 0.4
0.00142 0.00134
151.05 117.78
bjective function values; CV, coefﬁcient of variation.
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cig. 1. Plot of remaining unabsorbed vicenin-2 as a percentage of the initial concent
he  solid lines represent individual Bayesian predicted values and dotted lines are 
ymbols.
. The minimum objective function values (MOFV) in Table 1 were
omparable for all ﬁve models, except for Model 4, which was
pproximately 33 points greater than the other four models. The
aturable absorption model (Model 3) was considered unstable
iven that the magnitude of the standard error of the parameter
stimates was very large ranging from 84% to 295%.
We initially evaluated Model 2 given that the active secretion is
 saturable process. The parameter estimates were 0.28 min−1 for
he ﬁrst order absorption rate constant ka, 17.2% min–1 and 18.2%
or Vms and Kms of the active secretion process, respectively. The
elative standard error of the parameter estimates ranged from 1.8%
o 9.2%, which were markedly smaller than those of Model 3. We
urther evaluated a reduced model by using a zero-order secretion
rocess to replace the Michaelis–Menten process (Model 1). The
OFV of Models 1 and 2 were identical, suggesting that the more
omplex Michaelis–Menten active secretion does not provide sig-
iﬁcant advantage over the more parsimonious zero-order process.
he parameters of Model 1 were 0.274 min−1 and 16.3% min−1 for
a and zero-order secretion k0, respectively. The precision of the
harmacokinetic parameters and their variability were considered
cceptable for both Models 1 and 2.
The absorption proﬁles of vicenin-2 in the ﬁve rats are plotted
n Fig. 1 with the remaining amount as a percentage of the origi-
al dose versus time represented by triangle symbols. The model ﬁt
f Eq. (1), which has ﬁrst-order absorption and zero-order secre-
ion processes, to the observed data are represented as dashed
ines and solid lines for the population predicted and individual
redicted curves in the same ﬁgure, respectively. Given the iden-
ical MOFV of both Models 1 and 2, the individual plot of Model
 is identical to that shown in Fig. 1. The plot for each animal is
resented with the top panel strip indicated by animal number.
here was a good agreement between model prediction and the
bserved percentage unabsorbed vicenin-2. The plots of the model
redicted (PRED) and individual predicted (IPRED) concentrations
ersus observed data (OBS) are shown on the top graphs of Fig. 3
or the ﬁnal model describing vicenin-2 intestinal absorption. The
onditional weighted residuals (CWRES) versus time and CWRES in the intestinal lumen versus time using the rat single-pass perfusion model (n = 5).
pulation-predicted values. The actual observed data are represented by triangular
versus PRED plots in the bottom graphs of Fig. 2 show that most of
the data lies within 2 units from the zero-ordinate.
From the individual plots and the diagnostic plot of CWRES
versus TIME in Figs. 1 and 2 respectively, we noticed an
alternating sinusoidal pattern with a period of approximately
25 min. A sinusoidal function cos2t + 1 was  incorporated to the
Michaelis–Menten and zero-order secretion processes in Models 4
and 5. Given the range of values of a cosine function is between −1
and 1, the cosine function was squared and translated by 1 unit to
avoid negative and zero values. Both models achieved successful
convergence but matrix singularity was  encountered. Incorporat-
ing the sinusoidal function did not give an advantage over the
reduced models 1 and 2, as the MOFVs were either the same or
increased.
The bootstrap analyses for both Models 1 and 2 are reported in
Table 2. The median values were similar to the population param-
eter estimates of the original data and the 95% conﬁdence interval
(CI) contained the parameter estimates for Model 1. The param-
eters of the Michaelis–Menten active secretion process in Model
2 were smaller than the bootstrap median and mean, suggesting
that there may  be multiple local minima or possible parameter
non-identiﬁability for Vms and Kms. When interindividual variabil-
ity was  introduced to either Vms or Kms, model convergence was
achieved with boundary problems.
The degenerate visual predictive check in Fig. 3 showed that the
2.5th and 97.5th percentiles of the simulated results from Model 1
contained the individual data and the observed data. These diag-
nostics indicated that the population estimates in the ﬁnal model
were accurate and stable.
Discussion
Using the biopartitioning micellar chromatography (BMC), we
have previously demonstrated that the extent of vicenin-2 (1)
absorption was approximately 59% (Diniz et al., 2007). The result
from the current study using in situ single-pass intestinal perfusion
method showed a markedly lesser absorption of only 40.2 ± 2.5%.
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odel predicted concentrations; CWRES, conditional weighted residuals.
ecause the current study is performed in live animals, the active
ransport process is intact. The difference in the extent of absorp-
ion between the two techniques supported the notion that the
fﬂux pumps play an active role in limiting the absorption of
icenin-2, as vicenin-2 can only be absorbed through passive trans-
ort across the membrane in the BMC  assay (Molero-Monfort et al.,
able 2
tability of Models 1 and 2 using nonparametric bootstrap.
Model No. 1 
Mean (RSE%) Median (95% CI) 
Parameter
ka (min−1) 0.277 (10.6) 0.279 (0.217, 0.327) 
k0 (% min−1) 16.4 (9.0) 16.4 (13.1, 18.8)
Vms (% min−1) 
Kms (%) 
Interindividual variability
%CV of ka 7.7 (26) 8.4 (0.7, 11.1) 
Residual variability
Residual error 0.00151 (26) 0.00151 (0.00074, 0.002
MOFV  113.5 (8.7) 114.9 (83.0, 126.4) 
OFV, minimum objective function values; CI, conﬁdence interval; RSE, relative standardl. IPRED, individual predicted concentration; OBS, observed concentrations; PRED,
2001). The BMC  prediction method was  based on the chemical
properties of vicenin-2 and estimated a value 70% larger than what
the in vivo model had found.Absorption studies of vicenin-2 in Caco-2 cells showed
that vicenin-2 were not absorbed in the conditions that were
tested (Gouvea et al., 2014). The possible explanations for the
2
Mean (RSE%) Median (95% CI)
0.39 (18.8) 0.388 (0.285, 0.563)
35.5 (32.1) 36.7 (17.4, 61.0)
29.0 (51.7) 31.2 (0.98, 52.3)
4.0 (0.45, 9.3)
28) 0.00156 (28.2) 0.00157 (0.00074, 0.00242)
112.8 (9.7) 114.2 (83.0, 127.8)
 error; CV, coefﬁcient of variation.
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iscrepancies between their study and the current study are low
oses and the site of absorption. The investigators using Caco-2
ells tested only low concentrations at 25 and 50 M vicenin-2,
hereas the present study used a dose of 180 mg  kg−1. At this dose,
he concentration of drug at the absorption site is approximately
.6 mg  ml−1, which is equivalent to 6000 M.  It is likely that the
ermeation process may  also be different in the colon versus that
n the small intestine. Caco-2 cells are derived from colon cancer
ells whereas majority of vicenin-2 absorption in the in vivo model
n the current study is likely to have occurred in the small intestine.
The single pass intestinal perfusion technique illustrated that
he rate of vicenin-2 absorption was rapid but the extent of absorp-
ion at 40% can be classiﬁed as poorly absorbed. The collective
nformation points to vicenin-2 being absorbed by the small intes-
ine but not likely absorbed in the colon. This pharmacokinetic
haracteristic of vicenin-2 suggests the potential for this compound
s a local anti-inﬂammatory or anti-oxidative agent for intesti-
al diseases. This property may  possibly explain how extracts
rom L. ericoides were effective both as a prophylactic agent and
reatment for colon cancer in the animal model (Fernandes et al.,
011). The dose of 90 mg  kg−1 exhibited efﬁcacious systemic anti-
nﬂammatory activity (Gobbo-Neto et al., 2005) but higher dose
180 mg  kg−1) was used in this work in order to guarantee that
he remaining concentration is measurable by HPLC assuming a
apid intestinal absorption of vicenin-2. The result suggests that
he extent of vicenin-2 absorption in the small intestine could be
ufﬁcient to elicit pharmacological effect at the site of action. The
nformation generated from this study can be useful for guiding
argets and formulations for the potential development of novel
hytomedicines containing vicenin-2 against colon cancer, Crohn’s
isease and other intestinal inﬂammatory injuries. However, more
tudies are still needed to conﬁrm this hypothesis.
This study also evaluated the kinetics of vicenin-2
bsorption using a ﬁrst-order absorption and zero-order or
ichaelis–Menten type secretion into the intestinal lumen. The
ichaelis–Menten secretion process combined with either ﬁrst
rder or Michaelis–Menten or the combination of both for absorp-
ion was previously used to describe the absorption behavior of
itonavir in rats, also assuming that ritonavir is subject to efﬂux
ransport (Munoz et al., 2005). The investigators have shown thatrmacognosia 25 (2015) 212–218 217
the application of two  Michaelis–Menten functions may  lead to
instability and the Michaelis–Menten active secretion process can
be collapsed to a zero-order process. Their results corroborated
with our ﬁndings. Our study has shown that further model reduc-
tion to a ﬁrst-order absorption and zero-order secretion processes
can adequately describe the absorption kinetics of vicenin-2. The
differences in the two modeling strategy were that their study was
conducted in four doses whereas our study had only one dose level,
and their models were ﬁtted to the drug concentrations reported
in micromolar unit whereas the data from the present study were
modeled on the percent of the dose that was unabsorbed. The
models utilized in this study described well the absorption proﬁles
of vicenin-2 in the in vivo rat model.
In summary, the absorption of vicenin-2 is complex and likely
non-linear. This study characterized the gastro-intestinal absorp-
tion kinetics of vicenin-2 and had shown the potential role of active
secretion into the lumen of live animals. Further investigation of
vicenin-2 as an oral pharmacological agent is supported by the
ﬁndings of this study.
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